Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;21(1):14.
doi: 10.3892/etm.2020.9446. Epub 2020 Nov 4.

Short- and long-term treatment with angiotensin-converting enzyme inhibitors or calcium channel blockers for the prevention of diabetic nephropathy progression: A meta-analysis

Jialang Liang  1 , Jiarong Lan  2 , Qizhi Tang  1 , Wenjing Ling  3 , Min Li  4
Affiliations

Short- and long-term treatment with angiotensin-converting enzyme inhibitors or calcium channel blockers for the prevention of diabetic nephropathy progression: A meta-analysis

Jialang Liang et al. Exp Ther Med. 2021 Jan.

Abstract

Treatments with angiotensin-converting enzyme (ACE) inhibitors or calcium channel blockers (CCBs) may delay the development of albuminuria in patients with early diabetic nephropathy. However, evidence in the literature has not been consistent. The present meta-analysis aimed to compare the short- and long-term therapeutic effects of ACE inhibitors and CCBs (when used separately) for preventing the progression of nephropathy in patients with diabetes mellitus. A comprehensive search of various databases was performed from inception until March 2015 for studies in the Chinese and English languages. Randomized controlled trials (RCTs) comparing the efficacy of ACE inhibitors with that of CCBs in patients with early diabetic nephropathy were considered. A total of 12 RCTs were included with a total of 947 patients. ACE inhibitors were indicated to be more effective in reducing the albumin excretion rate than CCBs after short-term treatments (<6 months) [mean difference (MD), 32.35; 95% confidence interval (CI), 31.62-33.07; P<0.00001]. There was no difference in serum creatinine values after treatment with either drug (MD, 8.7; 95% CI, -21.5-38.91; P=0.57). Data from six studies were used to compare long-term treatment effects (≥1 year). In terms of progression to normoalbuminuria, a marginal difference was obtained between the two drugs with better outcomes with ACE inhibitors [odds ratio (OR), 0.70; 95% CI, 0.49-1.00; P=0.05]. There was no statistically significant difference between ACE inhibitors and CCBs regarding the progression from microalbuminuria to macroalbuminuria (OR, 1.78; 95% CI, 0.82-3.87; P=0.15). In conclusion, the present study indicated that the antiproteinuric efficacy of CCBs may be less than that of ACE inhibitors after short-term treatment in patients with DN. However, both types of drugs are equally effective in reducing the progression of microalbuminuria to macroalbuminuria in the long term.

Keywords: angiotensin-converting enzyme inhibitors; calcium channel blockers; early diabetic nephropathy; meta-analysis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of study selection.
Figure 2
Figure 2
Effect of ACE inhibitors and CCB on the albumin excretion rate. IV, inverse variance; SD, standard deviation; df, degrees of freedom; ACE, angiotensin-converting enzyme inhibitors; CCB, calcium channel blockers.
Figure 3
Figure 3
Effect of ACE inhibitors and CCB on serum creatinine. IV, inverse variance; SD, standard deviation; df, degrees of freedom; ACE, angiotensin-converting enzyme inhibitors; CCB, calcium channel blockers.
Figure 4
Figure 4
Effect of ACE inhibitors and CCB on the progression to normoalbuminuria. df, degrees of freedom; ACE, angiotensin-converting enzyme inhibitors; CCB, calcium channel blockers; M-H, Mantel-Haentzel.
Figure 5
Figure 5
Effect of ACE inhibitors and CCB on the progression to macroalbuminuria. df, degrees of freedom; ACE, angiotensin-converting enzyme inhibitors; CCB, calcium channel blockers; M-H, Mantel-Haentzel.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–1053. doi: 10.2337/diacare.27.5.1047. - DOI - PubMed
    1. Standards of medical care in diabetes - 2011. Diabetes Care. 2011;34 (Suppl 1):S11–S61. doi: 10.2337/dc11-S011. American Diabetes Association. - DOI - PMC - PubMed
    1. Hajhosseiny R, Khavandi K, Jivraj N, Mashayekhi S, Goldsmith DJ, Malik RA. Have we reached the limits for the treatment of diabetic nephropathy? Expert Opin Investig Drugs. 2014;23:511–522. doi: 10.1517/13543784.2014.892580. - DOI - PubMed
    1. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253–259. Heart Outcomes Prevention Evaluation Study Investigators. - PubMed
    1. Hu R, Yang Z. Study on effect of the combined treatment of enalapril and amlodipine in elderly diabetic patients with hypertension. Diabetes New World. 2014;24:6–7. (In Chinese)

LinkOut - more resources